Constitutive expression of bcl-2 in B cells causes a lethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H- 2b alloantigens

The bcl-2 protooncogene has been shown to provide a survival signal to self-reactive B cells, but it fails to override their developmental arrest after encounter with antigen. Furthermore, constitutive expression of bcl-2 in B cells does not promote the development of autoimmune disease in most strains of mice, indicating that signals other than those conferred by bcl-2 are required for long-term survival and differentiation of self-reactive B cells in vivo. To further examine the factors that are required for the pathogenesis of autoimmune disease, we have assessed the effect of bcl-2 overexpression on the development of host-versus-graft disease, a self-limited model of systemic autoimmune disease. In this model, injection of spleen cells from (C57BL/6 x BALB/c)F1 hybrid mice into BALB/c newborn parental mice induces immunological tolerance to donor tissues and activation of autoreactive F1 donor B cells through interactions provided by allogeneic host CD4+ T cells. BALB/c newborns injected with spleen cells from (C57BL/6 x BALB/c)F1 mice expressing a bcl-2 transgene in B cells developed high levels of anti-single-stranded DNA and a wide range of pathogenic autoantibodies that were not or barely detectable in mice injected with nontransgenic spleen cells. In mice injected with transgenic B cells, the levels of pathogenic autoantibodies remained high during the course of the study and were associated with long-term persistence of donor B cells, development of a severe autoimmune disease, and accelerated mortality. These results demonstrate that bcl-2 can provide survival signals for the maintenance and differentiation of autoreactive B cells, and suggest that both increased B cell survival and T cell help play critical roles in the development of certain forms of systemic autoimmune disease.

[1]  J. Merino,et al.  Differences in non-MHC alloantigens promote tissue rejection but fail to mediate allogeneic co-operation and autoimmunity in mice neonatally injected with semi-allogeneic F1 B cells. , 1994, Immunology.

[2]  L. Ding,et al.  Developmental regulation of the Bcl‐2 protein and susceptibility to cell death in B lymphocytes. , 1994, The EMBO journal.

[3]  G. J. V. Nossal,et al.  Negative selection of lymphocytes , 1994, Cell.

[4]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[5]  T. Honjo,et al.  The bcl-2 gene product inhibits clonal deletion of self-reactive B lymphocytes in the periphery but not in the bone marrow , 1993, The Journal of experimental medicine.

[6]  V. Stewart,et al.  Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. , 1993, Science.

[7]  R. Hardy,et al.  The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver , 1993, The Journal of experimental medicine.

[8]  J. Merino,et al.  Autoimmune syndrome after induction of neonatal tolerance to I‐E antigens , 1993, European journal of immunology.

[9]  M. Cooke,et al.  Elimination of self-reactive B lymphocytes proceeds in two stages: Arrested development and cell death , 1993, Cell.

[10]  D. Abramowicz,et al.  Neonatal induction of transplantation tolerance in mice is associated with in vivo expression of IL-4 and -10 mRNAs. , 1993, Transplantation proceedings.

[11]  J C Reed,et al.  Differential effects of Bcl-2 on T and B cells in transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Vaux,et al.  Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Korsmeyer,et al.  Bcl-2 maintains B cell memory , 1991, Nature.

[14]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Schurmans,et al.  Transient T and B cell activation after neonatal induction of tolerance to MHC class II or Mls alloantigens. , 1991, Journal of immunology.

[16]  S. Schurmans,et al.  In vivo effects of anti-IL-4 monoclonal antibody on neonatal induction of tolerance and on an associated autoimmune syndrome. , 1990, Journal of immunology.

[17]  D. Mason,et al.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. , 1990, The American journal of pathology.

[18]  M. Gershwin,et al.  The BM12 mutation and autoantibodies to dsDNA in NZB.H-2bm12 mice. , 1990, Journal of immunology.

[19]  J. Streilein,et al.  Neonatal tolerance induction by class II alloantigens activates IL-4-secreting, tolerogen-responsive T cells. , 1990, Journal of immunology.

[20]  S. Izui,et al.  Differential effect of the autoimmune yaa and ipr genes on the acceleration of lupus‐like syndrome in mrl/mpj mice , 1989, European journal of immunology.

[21]  S. Schurmans,et al.  Autoimmune syndrome after induction of neonatal tolerance to alloantigens. CD4+ T cells from the tolerant host activate autoreactive F1 B cells. , 1989, Journal of immunology.

[22]  S. Izui,et al.  Autoantibody repertoire analysis in normal and lupus-prone mice. , 1989, Journal of autoimmunity.

[23]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[24]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.

[25]  A. Rolink,et al.  The autoantigen-binding B cell repertoires of normal and of chronically graft-versus-host-diseased mice , 1987, The Journal of experimental medicine.

[26]  G. Nossal,et al.  Clonal analysis of the anti-DNA repertoire of murine B lymphocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Lambert,et al.  Autoimmunity after induction of neonatal tolerance to alloantigens: role of B cell chimerism and F1 donor B cell activation. , 1986, Journal of immunology.

[28]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[29]  W. Seaman,et al.  Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4 , 1985, The Journal of experimental medicine.

[30]  A. Theofilopoulos,et al.  Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus , 1979, The Journal of experimental medicine.

[31]  B. Kullgren,et al.  Etiology, pathogenesis, and prevention of a fatal host-versus-graft syndrome in parent-F1 mouse chimeras. , 1970, The American journal of pathology.

[32]  L. Buelta,et al.  Self-limited autoimmune disease related to transient donor B cell activation in mice neonatally injected with semi-allogeneic F1 cells. , 1992, International immunology.

[33]  D. Abramowicz,et al.  Renal immunopathology in murine host-versus-graft disease. , 1991, Kidney international.

[34]  S. Schurmans,et al.  Autoimmune syndrome after neonatal induction of tolerance to alloantigens: analysis of the specificity and of the cellular and genetic origin of autoantibodies. , 1991, Autoimmunity.

[35]  S. Schurmans,et al.  Expression of anti-DNA clonotypes and the role of helper T-lymphocytes during the autoimmune response in mice tolerant to alloantigens. , 1988, Autoimmunity.